[
    [
        "NCT00066573",
        "1adc970c-d433-44d0-aa09-d3834986f7a2",
        "1adc970c-d433-44d0-aa09-d3834986f7a2_b",
        "there is a 13.2% difference between the results from the two the primary trial cohorts",
        "There was a 13.2% difference between the results of the two primary trial cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00066573",
        "1adc970c-d433-44d0-aa09-d3834986f7a2",
        "fe876bb0-7ce3-4197-81ad-920f1f77938e",
        "there is a 13.2% difference between the results from the two the primary trial cohorts",
        "there is a minimal difference between the results from the two the primary trial cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00066573",
        "fe876bb0-7ce3-4197-81ad-920f1f77938e",
        "1adc970c-d433-44d0-aa09-d3834986f7a2",
        "there is a minimal difference between the results from the two the primary trial cohorts",
        "there is a 13.2% difference between the results from the two the primary trial cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00066573",
        "fe876bb0-7ce3-4197-81ad-920f1f77938e",
        "fe876bb0-7ce3-4197-81ad-920f1f77938e_b",
        "there is a minimal difference between the results from the two the primary trial cohorts",
        "Small differences between the results of the two primary trial cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00425854_NCT01224678",
        "6b9162d0-0816-46d4-81af-c60028dcc63b",
        "6b9162d0-0816-46d4-81af-c60028dcc63b_b",
        "Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over",
        "Patients with significantly elevated ejection fraction were excluded from the primary trial, but were still eligible for the secondary trial if they were 55 or older",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00425854_NCT01224678",
        "6b9162d0-0816-46d4-81af-c60028dcc63b",
        "d1b7105d-0b7d-4b10-92a7-d63243ff0629",
        "Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over",
        "Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger ",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00425854_NCT01224678",
        "d1b7105d-0b7d-4b10-92a7-d63243ff0629",
        "6b9162d0-0816-46d4-81af-c60028dcc63b",
        "Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger ",
        "Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00425854_NCT01224678",
        "d1b7105d-0b7d-4b10-92a7-d63243ff0629",
        "d1b7105d-0b7d-4b10-92a7-d63243ff0629_b",
        "Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger ",
        "Patients with significantly lower ejection fraction were excluded from the primary trial, but were still eligible for the secondary trial if they were under 55 years of age",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02273973_NCT00281697",
        "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f",
        "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f_b",
        "a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis",
        "A substantial number of participants in the secondary and primary trials had enterocolitis",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02273973_NCT00281697",
        "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f",
        "2ef186d0-b4ab-44de-b785-a63e9e95851a",
        "a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis",
        "most participants in the secondary trial and the primary trial did not suffer from Enterocolitis",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02273973_NCT00281697",
        "2ef186d0-b4ab-44de-b785-a63e9e95851a",
        "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f",
        "most participants in the secondary trial and the primary trial did not suffer from Enterocolitis",
        "a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02273973_NCT00281697",
        "2ef186d0-b4ab-44de-b785-a63e9e95851a",
        "2ef186d0-b4ab-44de-b785-a63e9e95851a_b",
        "most participants in the secondary trial and the primary trial did not suffer from Enterocolitis",
        "Most participants in secondary and primary trials did not have enterocolitis",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00593346",
        "cc1f712a-2116-4e40-9810-f315e3fa5ff8",
        "cc1f712a-2116-4e40-9810-f315e3fa5ff8_b",
        "the primary trial does not report the PFS or objective response rate of its patient cohort",
        "Primary trials did not report PFS or objective response rates for their patient cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00593346",
        "cc1f712a-2116-4e40-9810-f315e3fa5ff8",
        "88668508-dfd4-4a39-91cd-cf1654a6dfc4",
        "the primary trial does not report the PFS or objective response rate of its patient cohort",
        "the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00593346",
        "88668508-dfd4-4a39-91cd-cf1654a6dfc4",
        "cc1f712a-2116-4e40-9810-f315e3fa5ff8",
        "the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis",
        "the primary trial does not report the PFS or objective response rate of its patient cohort",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00593346",
        "88668508-dfd4-4a39-91cd-cf1654a6dfc4",
        "88668508-dfd4-4a39-91cd-cf1654a6dfc4_b",
        "the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis",
        "Primary trials do not report PFS or objective response rates for their patient cohorts, but rather the proportion of patients experiencing dermatitis",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02340221",
        "904061c0-14fa-4f13-9118-9a41e24fa8eb",
        "904061c0-14fa-4f13-9118-9a41e24fa8eb_b",
        "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial",
        "Prior treatment with fulvestrant or phosphatidylinositol 3-kinase ( PI3K ) inhibitors did not prevent patients from enrolling in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02340221",
        "904061c0-14fa-4f13-9118-9a41e24fa8eb",
        "6b35bc10-f591-4b84-abac-40a74be949fa",
        "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial",
        "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02340221",
        "6b35bc10-f591-4b84-abac-40a74be949fa",
        "904061c0-14fa-4f13-9118-9a41e24fa8eb",
        "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial",
        "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02340221",
        "6b35bc10-f591-4b84-abac-40a74be949fa",
        "6b35bc10-f591-4b84-abac-40a74be949fa_b",
        "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial",
        "treatment with fulvestrant or phosphatidylinositol 3-kinase (PI3K) inhibitors was not allowed in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00281697",
        "43ee7645-ce1e-42d5-9a74-3e379f6f367b",
        "43ee7645-ce1e-42d5-9a74-3e379f6f367b_b",
        "only patients with a HER2-positive status can take part in the primary trial",
        "Only patients with HER2-positive status will be eligible to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00281697",
        "43ee7645-ce1e-42d5-9a74-3e379f6f367b",
        "00822101-fa21-4a26-bf45-3b1f535da005",
        "only patients with a HER2-positive status can take part in the primary trial",
        "a patient with a HER2-positive status can not take part in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00281697",
        "00822101-fa21-4a26-bf45-3b1f535da005",
        "43ee7645-ce1e-42d5-9a74-3e379f6f367b",
        "a patient with a HER2-positive status can not take part in the primary trial",
        "only patients with a HER2-positive status can take part in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00281697",
        "00822101-fa21-4a26-bf45-3b1f535da005",
        "00822101-fa21-4a26-bf45-3b1f535da005_b",
        "a patient with a HER2-positive status can not take part in the primary trial",
        "HER2-positive patients cannot participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00915603",
        "0cef8c8e-7986-46c7-a597-c5733a9899c0",
        "0cef8c8e-7986-46c7-a597-c5733a9899c0_b",
        "the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months",
        "The shortest PFS in the primary trial cohort 1 was less than 7 months and the shortest PFS in cohort 2 was just over 7 months",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00915603",
        "0cef8c8e-7986-46c7-a597-c5733a9899c0",
        "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7",
        "the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months",
        "at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00915603",
        "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7",
        "0cef8c8e-7986-46c7-a597-c5733a9899c0",
        "at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months",
        "the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00915603",
        "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7",
        "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7_b",
        "at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months",
        "Progression-free survival was 10.8 months with at least 2 primary trial participants (at least 1 participant in each cohort)",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01998906",
        "43ce26e5-03fa-4e9d-b0eb-6ea356295753",
        "43ce26e5-03fa-4e9d-b0eb-6ea356295753_b",
        "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks .",
        "The two cohorts of the primary trial underwent a total of 17 cycles, each lasting 3 weeks.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01998906",
        "43ce26e5-03fa-4e9d-b0eb-6ea356295753",
        "2a2c16a7-f427-4fdb-8153-94aac304e4b8",
        "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks .",
        "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01998906",
        "2a2c16a7-f427-4fdb-8153-94aac304e4b8",
        "43ce26e5-03fa-4e9d-b0eb-6ea356295753",
        "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles",
        "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks .",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01998906",
        "2a2c16a7-f427-4fdb-8153-94aac304e4b8",
        "2a2c16a7-f427-4fdb-8153-94aac304e4b8_b",
        "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles",
        "The two cohorts in the primary trial underwent a total of 17 cycles, each lasting 3 weeks, with patients receiving the same type and dose of drug for all 17 cycles",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00428922",
        "3facad41-0221-42f8-834d-470e65c4aad5",
        "3facad41-0221-42f8-834d-470e65c4aad5_b",
        "the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease ",
        "The outcome measure of the primary trial was the length of time patients survived during and after treatment",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00428922",
        "3facad41-0221-42f8-834d-470e65c4aad5",
        "d01fda83-5dc8-4ad5-92b8-7553dabd7046",
        "the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease ",
        "the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00428922",
        "d01fda83-5dc8-4ad5-92b8-7553dabd7046",
        "3facad41-0221-42f8-834d-470e65c4aad5",
        "the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse",
        "the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease ",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00428922",
        "d01fda83-5dc8-4ad5-92b8-7553dabd7046",
        "d01fda83-5dc8-4ad5-92b8-7553dabd7046_b",
        "the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse",
        "The outcome measure of the primary trial was the length of time patients had disease but did not get worse during and after treatment",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01912612",
        "9cbc00e9-3a2d-4471-a93e-72c95132fb6a",
        "9cbc00e9-3a2d-4471-a93e-72c95132fb6a_b",
        "The only case of congestive heart failure in the primary trial occurred in cohort 1",
        "The only case of congestive heart failure in the primary trial occurred in cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01912612",
        "9cbc00e9-3a2d-4471-a93e-72c95132fb6a",
        "d1b217ae-76f3-4ba6-958e-5b2558703ba4",
        "The only case of congestive heart failure in the primary trial occurred in cohort 1",
        "several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01912612",
        "d1b217ae-76f3-4ba6-958e-5b2558703ba4",
        "9cbc00e9-3a2d-4471-a93e-72c95132fb6a",
        "several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2",
        "The only case of congestive heart failure in the primary trial occurred in cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01912612",
        "d1b217ae-76f3-4ba6-958e-5b2558703ba4",
        "d1b217ae-76f3-4ba6-958e-5b2558703ba4_b",
        "several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2",
        "Several cases of congestive heart failure in the primary trial occurred in cohort 1 but none in cohort 2",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02419807",
        "8b91cab9-d858-45f3-bf8d-3d6fc55b4818",
        "8b91cab9-d858-45f3-bf8d-3d6fc55b4818_b",
        "The the primary trial results section reports two different measurements",
        "primary trial results section",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02419807",
        "8b91cab9-d858-45f3-bf8d-3d6fc55b4818",
        "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7",
        "The the primary trial results section reports two different measurements",
        "The the primary trial results section reports two different measurements, for all 3 cohorts.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02419807",
        "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7",
        "8b91cab9-d858-45f3-bf8d-3d6fc55b4818",
        "The the primary trial results section reports two different measurements, for all 3 cohorts.",
        "The the primary trial results section reports two different measurements",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02419807",
        "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7",
        "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7_b",
        "The the primary trial results section reports two different measurements, for all 3 cohorts.",
        "The primary trial results section reports two different measures for all 3 cohorts .",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00022516",
        "4a75574c-fa86-4e62-a210-81c7b98a3807",
        "4a75574c-fa86-4e62-a210-81c7b98a3807_b",
        "T4 N2 M4 patients are eligible for the primary trial",
        "T4 N2 M4 patients eligible for primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00022516",
        "4a75574c-fa86-4e62-a210-81c7b98a3807",
        "978d19fc-e7f6-485e-b8bd-cfcde06441ab",
        "T4 N2 M4 patients are eligible for the primary trial",
        "T1 N0 M0 patients are eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00022516",
        "978d19fc-e7f6-485e-b8bd-cfcde06441ab",
        "4a75574c-fa86-4e62-a210-81c7b98a3807",
        "T1 N0 M0 patients are eligible for the primary trial",
        "T4 N2 M4 patients are eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00022516",
        "978d19fc-e7f6-485e-b8bd-cfcde06441ab",
        "978d19fc-e7f6-485e-b8bd-cfcde06441ab_b",
        "T1 N0 M0 patients are eligible for the primary trial",
        "T1 N0 M0 patients eligible for primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT03098550",
        "b0b61978-57db-4a1c-812c-509e8b05f2dc",
        "b0b61978-57db-4a1c-812c-509e8b05f2dc_b",
        "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have",
        "Both cohorts in the primary trial received the same intervention, with the difference between the two cohorts being the type of cancer the patients had",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT03098550",
        "b0b61978-57db-4a1c-812c-509e8b05f2dc",
        "3adcc8fc-b76b-407a-a006-729a13f571fb",
        "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have",
        "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT03098550",
        "3adcc8fc-b76b-407a-a006-729a13f571fb",
        "b0b61978-57db-4a1c-812c-509e8b05f2dc",
        "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-",
        "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT03098550",
        "3adcc8fc-b76b-407a-a006-729a13f571fb",
        "3adcc8fc-b76b-407a-a006-729a13f571fb_b",
        "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-",
        "Both cohorts in the primary trial received the same intervention and the difference between the two cohorts was the type of cancer the patients had, with cohort 1 both diagnosed with HER2-positive cancer and cohort 2 PR-",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01929395",
        "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1",
        "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1_b",
        "Patients must have a palpable carcinoma to be included in the primary trial",
        "Patients must have palpable cancer to be included in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01929395",
        "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1",
        "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2",
        "Patients must have a palpable carcinoma to be included in the primary trial",
        "Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01929395",
        "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2",
        "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1",
        "Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial",
        "Patients must have a palpable carcinoma to be included in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01929395",
        "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2",
        "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2_b",
        "Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial",
        "Patients had to have several visible cancers in the stomach and neck area to be included in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT03176238",
        "fbb62216-2cf2-4813-ad41-12a86940610f",
        "fbb62216-2cf2-4813-ad41-12a86940610f_b",
        "Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial",
        "Anemia was the most common adverse event in the primary trial cohorts 1 and 2",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT03176238",
        "fbb62216-2cf2-4813-ad41-12a86940610f",
        "ec1e269e-470d-43d9-8f23-8a19a5c96fcc",
        "Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial",
        "Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT03176238",
        "ec1e269e-470d-43d9-8f23-8a19a5c96fcc",
        "fbb62216-2cf2-4813-ad41-12a86940610f",
        "Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2",
        "Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT03176238",
        "ec1e269e-470d-43d9-8f23-8a19a5c96fcc",
        "ec1e269e-470d-43d9-8f23-8a19a5c96fcc_b",
        "Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2",
        "Anemia was the most common adverse event in primary trial cohort 1 and tachycardia was the most common adverse event in cohort 2",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01644890",
        "961a956e-fece-4baa-a2ad-d3a5320bd9d2",
        "961a956e-fece-4baa-a2ad-d3a5320bd9d2_b",
        "The shortest PFS in cohort 1 of the primary trial was less than 3 weeks",
        "The shortest PFS in the primary trial cohort 1 was less than 3 weeks",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01644890",
        "961a956e-fece-4baa-a2ad-d3a5320bd9d2",
        "8c6314f7-34f5-42a7-ba66-b95d050a6315",
        "The shortest PFS in cohort 1 of the primary trial was less than 3 weeks",
        "The shortest PFS in cohort 1 of the primary trial was 1.4 months below average",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01644890",
        "8c6314f7-34f5-42a7-ba66-b95d050a6315",
        "961a956e-fece-4baa-a2ad-d3a5320bd9d2",
        "The shortest PFS in cohort 1 of the primary trial was 1.4 months below average",
        "The shortest PFS in cohort 1 of the primary trial was less than 3 weeks",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01644890",
        "8c6314f7-34f5-42a7-ba66-b95d050a6315",
        "8c6314f7-34f5-42a7-ba66-b95d050a6315_b",
        "The shortest PFS in cohort 1 of the primary trial was 1.4 months below average",
        "The shortest PFS in the primary trial cohort 1 was 1.4 months below average",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00328783",
        "97fd111c-6969-43ab-93af-b3dff09960e5",
        "97fd111c-6969-43ab-93af-b3dff09960e5_b",
        "The adverse events section in the primary trial is reports the incidence rate of 12 different Aes",
        "Incidence of Aes",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00328783",
        "97fd111c-6969-43ab-93af-b3dff09960e5",
        "fef5aedb-21c0-4130-b8a3-cb1df5017c7a",
        "The adverse events section in the primary trial is reports the incidence rate of 12 different Aes",
        "The adverse events section in the primary trial is empty",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00328783",
        "fef5aedb-21c0-4130-b8a3-cb1df5017c7a",
        "97fd111c-6969-43ab-93af-b3dff09960e5",
        "The adverse events section in the primary trial is empty",
        "The adverse events section in the primary trial is reports the incidence rate of 12 different Aes",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00328783",
        "fef5aedb-21c0-4130-b8a3-cb1df5017c7a",
        "fef5aedb-21c0-4130-b8a3-cb1df5017c7a_b",
        "The adverse events section in the primary trial is empty",
        "The Adverse Events section in the primary trial is empty",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00191789_NCT00876395",
        "eb1bfb08-eba0-4130-b328-00f56c0f84a6",
        "eb1bfb08-eba0-4130-b328-00f56c0f84a6_b",
        "Diarrhoea is the most common adverse event in the primary trial and the secondary trial",
        "Diarrhea was the most common adverse event in the primary and secondary trials",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00191789_NCT00876395",
        "eb1bfb08-eba0-4130-b328-00f56c0f84a6",
        "324562e6-2b61-4a07-b937-86f99689f2d5",
        "Diarrhoea is the most common adverse event in the primary trial and the secondary trial",
        "Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00191789_NCT00876395",
        "324562e6-2b61-4a07-b937-86f99689f2d5",
        "eb1bfb08-eba0-4130-b328-00f56c0f84a6",
        "Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial",
        "Diarrhoea is the most common adverse event in the primary trial and the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00191789_NCT00876395",
        "324562e6-2b61-4a07-b937-86f99689f2d5",
        "324562e6-2b61-4a07-b937-86f99689f2d5_b",
        "Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial",
        "Diarrhea was the most common adverse event in the primary trial, while anemia was the most common adverse event in the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00274469",
        "b1219e71-fbf5-4bba-8a93-a27ae444e3e1",
        "b1219e71-fbf5-4bba-8a93-a27ae444e3e1_b",
        "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer",
        "To be eligible for the primary trial, patients must have been diagnosed with hormone receptor-positive advanced breast cancer and not have received any prior treatment for that advanced cancer",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00274469",
        "b1219e71-fbf5-4bba-8a93-a27ae444e3e1",
        "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65",
        "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer",
        "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00274469",
        "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65",
        "b1219e71-fbf5-4bba-8a93-a27ae444e3e1",
        "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.",
        "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00274469",
        "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65",
        "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65_b",
        "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.",
        "Patients eligible for the primary trial had to have been diagnosed with hormone receptor-positive advanced breast cancer and had previously received chemotherapy for that cancer.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00438100",
        "f10f3b84-e039-4a02-a98b-86d149d9a16f",
        "f10f3b84-e039-4a02-a98b-86d149d9a16f_b",
        "ongoing flucytosine treatments are not permitted for participants of the primary trial",
        "Continuing flucytosine treatment was not permitted for participants in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00438100",
        "f10f3b84-e039-4a02-a98b-86d149d9a16f",
        "565d7982-aa9a-4c01-987c-1d67bc9c212d",
        "ongoing flucytosine treatments are not permitted for participants of the primary trial",
        "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00438100",
        "565d7982-aa9a-4c01-987c-1d67bc9c212d",
        "f10f3b84-e039-4a02-a98b-86d149d9a16f",
        "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry",
        "ongoing flucytosine treatments are not permitted for participants of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00438100",
        "565d7982-aa9a-4c01-987c-1d67bc9c212d",
        "565d7982-aa9a-4c01-987c-1d67bc9c212d_b",
        "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry",
        "All participants in the primary trial will require continuous flucytosine treatment, which must have started at least 6 months before the start of the study",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01118624",
        "0ddb07ae-6e70-436d-8723-f609e59c57da",
        "0ddb07ae-6e70-436d-8723-f609e59c57da_b",
        "the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight",
        "Primary trial participants received weight-based doses of pralatrexate",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01118624",
        "0ddb07ae-6e70-436d-8723-f609e59c57da",
        "e9a4bd91-f58b-4234-9037-75e0699d1bbd",
        "the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight",
        "the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01118624",
        "e9a4bd91-f58b-4234-9037-75e0699d1bbd",
        "0ddb07ae-6e70-436d-8723-f609e59c57da",
        "the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate",
        "the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01118624",
        "e9a4bd91-f58b-4234-9037-75e0699d1bbd",
        "e9a4bd91-f58b-4234-9037-75e0699d1bbd_b",
        "the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate",
        "Primary trial participants received pralatrexate doses below 300 mg/m^2",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02924883",
        "c10eea1a-5768-442d-ae07-20b4f8f4b583",
        "c10eea1a-5768-442d-ae07-20b4f8f4b583_b",
        "Only patients with triple negative breast cancer are eligible for the primary trial",
        "Only patients with triple-negative breast cancer eligible for primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02924883",
        "c10eea1a-5768-442d-ae07-20b4f8f4b583",
        "446f3c69-0de5-475c-a8e2-ff40ece90672",
        "Only patients with triple negative breast cancer are eligible for the primary trial",
        "Only patients with HER2+ve breast cancer are eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02924883",
        "446f3c69-0de5-475c-a8e2-ff40ece90672",
        "c10eea1a-5768-442d-ae07-20b4f8f4b583",
        "Only patients with HER2+ve breast cancer are eligible for the primary trial",
        "Only patients with triple negative breast cancer are eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02924883",
        "446f3c69-0de5-475c-a8e2-ff40ece90672",
        "446f3c69-0de5-475c-a8e2-ff40ece90672_b",
        "Only patients with HER2+ve breast cancer are eligible for the primary trial",
        "Only patients with HER2+ve breast cancer eligible for primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01905592",
        "2655c892-216e-4b96-a8f2-6f64403215c5",
        "2655c892-216e-4b96-a8f2-6f64403215c5_b",
        "there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        "There were 4 types of adverse events that did not affect any patients in the primary trial cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01905592",
        "2655c892-216e-4b96-a8f2-6f64403215c5",
        "30483d7e-7703-459c-bd10-e2bd259c2a4f",
        "there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        "there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01905592",
        "30483d7e-7703-459c-bd10-e2bd259c2a4f",
        "2655c892-216e-4b96-a8f2-6f64403215c5",
        "there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        "there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01905592",
        "30483d7e-7703-459c-bd10-e2bd259c2a4f",
        "30483d7e-7703-459c-bd10-e2bd259c2a4f_b",
        "there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        "There were two types of adverse events that did not affect any patients in the primary trial cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02186015",
        "2825d63b-8f22-4fb8-829f-9567845251c6",
        "2825d63b-8f22-4fb8-829f-9567845251c6_b",
        "adults and children can take part in the primary trial",
        "Both adults and children can participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02186015",
        "2825d63b-8f22-4fb8-829f-9567845251c6",
        "a805f174-2707-4302-a195-05153ea8523e",
        "adults and children can take part in the primary trial",
        "Only adults can take part in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02186015",
        "a805f174-2707-4302-a195-05153ea8523e",
        "2825d63b-8f22-4fb8-829f-9567845251c6",
        "Only adults can take part in the primary trial",
        "adults and children can take part in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02186015",
        "a805f174-2707-4302-a195-05153ea8523e",
        "a805f174-2707-4302-a195-05153ea8523e_b",
        "Only adults can take part in the primary trial",
        "Only adults can participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01439945_NCT01998906",
        "a5baab2c-9c32-4301-a574-4ba5a0c2eb00",
        "a5baab2c-9c32-4301-a574-4ba5a0c2eb00_b",
        "Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "All patients who wish to participate in the primary or secondary trials will need to have had hot flashes for at least 4 months prior to study enrollment.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01439945_NCT01998906",
        "a5baab2c-9c32-4301-a574-4ba5a0c2eb00",
        "31105b43-832b-48bc-a78d-ee90c155ca44",
        "Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01439945_NCT01998906",
        "31105b43-832b-48bc-a78d-ee90c155ca44",
        "a5baab2c-9c32-4301-a574-4ba5a0c2eb00",
        "Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01439945_NCT01998906",
        "31105b43-832b-48bc-a78d-ee90c155ca44",
        "31105b43-832b-48bc-a78d-ee90c155ca44_b",
        "Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Hot flashes 30 days prior to study enrollment were required for all patients who wanted to enroll in the primary trial , but were not required for entry into the secondary trial.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00856492_NCT00009945",
        "70677d5f-7022-404c-8410-d1f89366d92f",
        "70677d5f-7022-404c-8410-d1f89366d92f_b",
        "the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.",
        "Both the secondary and primary trials measured pCR and tumor diameter in their patient cohorts.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00856492_NCT00009945",
        "70677d5f-7022-404c-8410-d1f89366d92f",
        "42d1fcd3-8faa-4065-bbba-42cc90ab67fb",
        "the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.",
        "the secondary trial and the primary trial do not both measure the pCR of their patient cohorts.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00856492_NCT00009945",
        "42d1fcd3-8faa-4065-bbba-42cc90ab67fb",
        "70677d5f-7022-404c-8410-d1f89366d92f",
        "the secondary trial and the primary trial do not both measure the pCR of their patient cohorts.",
        "the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00856492_NCT00009945",
        "42d1fcd3-8faa-4065-bbba-42cc90ab67fb",
        "42d1fcd3-8faa-4065-bbba-42cc90ab67fb_b",
        "the secondary trial and the primary trial do not both measure the pCR of their patient cohorts.",
        "Secondary and primary trials do not both measure pCR in their patient cohorts .",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02679755",
        "f46a7d27-a94f-4389-a1a0-4a8f5177b354",
        "f46a7d27-a94f-4389-a1a0-4a8f5177b354_b",
        "None of the individual Aes recorded in the primary trial affect more than than one patient",
        "None of the single Aes recorded in the primary trial affected more than one patient",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02679755",
        "f46a7d27-a94f-4389-a1a0-4a8f5177b354",
        "c09fa61c-967a-40ae-96b0-c87b7cde237b",
        "None of the individual Aes recorded in the primary trial affect more than than one patient",
        "None of the individual Aes recorded in the primary trial affect more than 10% of the population.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02679755",
        "c09fa61c-967a-40ae-96b0-c87b7cde237b",
        "f46a7d27-a94f-4389-a1a0-4a8f5177b354",
        "None of the individual Aes recorded in the primary trial affect more than 10% of the population.",
        "None of the individual Aes recorded in the primary trial affect more than than one patient",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02679755",
        "c09fa61c-967a-40ae-96b0-c87b7cde237b",
        "c09fa61c-967a-40ae-96b0-c87b7cde237b_b",
        "None of the individual Aes recorded in the primary trial affect more than 10% of the population.",
        "of the individual Aes affected more than 10% of the population.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00121992",
        "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929",
        "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929_b",
        "to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Candidates eligible for the primary trial must be at least 18 years old, have a severe disability, have normal liver, kidney and heart function, and have normal hematology levels.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00121992",
        "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929",
        "7c7418d2-32d7-4517-874b-eb3db24ea16a",
        "to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00121992",
        "7c7418d2-32d7-4517-874b-eb3db24ea16a",
        "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929",
        "to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00121992",
        "7c7418d2-32d7-4517-874b-eb3db24ea16a",
        "7c7418d2-32d7-4517-874b-eb3db24ea16a_b",
        "to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Candidates eligible to participate in the primary trial must be at least 18 years old, have a Karnofsky score over 80, and have adequate liver, kidney, and heart function and adequate hematology.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01042535",
        "4f705481-5dd0-414c-b375-c56e8c235b42",
        "4f705481-5dd0-414c-b375-c56e8c235b42_b",
        "The most common adverse event in the primary trial was skin infection",
        "Most common adverse event in primary trial was skin infection",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01042535",
        "4f705481-5dd0-414c-b375-c56e8c235b42",
        "16c29502-4683-4087-9410-ff1b786556f5",
        "The most common adverse event in the primary trial was skin infection",
        "The least common adverse event in the primary trial was Constipation ",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01042535",
        "16c29502-4683-4087-9410-ff1b786556f5",
        "4f705481-5dd0-414c-b375-c56e8c235b42",
        "The least common adverse event in the primary trial was Constipation ",
        "The most common adverse event in the primary trial was skin infection",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01042535",
        "16c29502-4683-4087-9410-ff1b786556f5",
        "16c29502-4683-4087-9410-ff1b786556f5_b",
        "The least common adverse event in the primary trial was Constipation ",
        "The least common adverse event in the primary trial was constipation",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00924352",
        "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2",
        "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2_b",
        "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial",
        "Febrile neutropenia was the most common adverse event recorded in the primary trial, affecting the majority of patients in the trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00924352",
        "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2",
        "1842904b-5371-49ee-b6f4-8831b879098b",
        "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial",
        "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00924352",
        "1842904b-5371-49ee-b6f4-8831b879098b",
        "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2",
        "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients",
        "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00924352",
        "1842904b-5371-49ee-b6f4-8831b879098b",
        "1842904b-5371-49ee-b6f4-8831b879098b_b",
        "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients",
        "Febrile neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02915744",
        "4309860d-042d-45a4-8a0a-a9fdd075247a",
        "4309860d-042d-45a4-8a0a-a9fdd075247a_b",
        "Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion",
        "Cohorts 1 and 2 of the primary trial did not receive infusions of NKTR-102",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02915744",
        "4309860d-042d-45a4-8a0a-a9fdd075247a",
        "8e9611fc-89f8-44cb-af09-8d71a13ca082",
        "Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion",
        "Cohort 1 and 2 of the primary trial do not receive the same intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02915744",
        "8e9611fc-89f8-44cb-af09-8d71a13ca082",
        "4309860d-042d-45a4-8a0a-a9fdd075247a",
        "Cohort 1 and 2 of the primary trial do not receive the same intervention",
        "Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02915744",
        "8e9611fc-89f8-44cb-af09-8d71a13ca082",
        "8e9611fc-89f8-44cb-af09-8d71a13ca082_b",
        "Cohort 1 and 2 of the primary trial do not receive the same intervention",
        "Cohorts 1 and 2 of the primary trial did not receive the same intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01262027_NCT02301988",
        "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85",
        "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85_b",
        "the primary trial and the secondary trial use identical outcome measurements",
        "Primary and secondary trials use the same outcome measure",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01262027_NCT02301988",
        "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85",
        "0131ebe3-746b-45a5-ba60-fdd326974fec",
        "the primary trial and the secondary trial use identical outcome measurements",
        "the primary trial and the secondary trial use comparable outcome measurements",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01262027_NCT02301988",
        "0131ebe3-746b-45a5-ba60-fdd326974fec",
        "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85",
        "the primary trial and the secondary trial use comparable outcome measurements",
        "the primary trial and the secondary trial use identical outcome measurements",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01262027_NCT02301988",
        "0131ebe3-746b-45a5-ba60-fdd326974fec",
        "0131ebe3-746b-45a5-ba60-fdd326974fec_b",
        "the primary trial and the secondary trial use comparable outcome measurements",
        "Primary and secondary trials using comparable outcome measures",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00503906",
        "59cd7909-00c3-4c23-9a08-a42dbc8eabdd",
        "59cd7909-00c3-4c23-9a08-a42dbc8eabdd_b",
        "Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression",
        "Participants in the primary trial will not receive the intervention for a number of cycles, which will continue until disease progression",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00503906",
        "59cd7909-00c3-4c23-9a08-a42dbc8eabdd",
        "6499b181-7a23-4073-8459-ad46ff02b20f",
        "Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression",
        "Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days)",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00503906",
        "6499b181-7a23-4073-8459-ad46ff02b20f",
        "59cd7909-00c3-4c23-9a08-a42dbc8eabdd",
        "Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days)",
        "Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00503906",
        "6499b181-7a23-4073-8459-ad46ff02b20f",
        "6499b181-7a23-4073-8459-ad46ff02b20f_b",
        "Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days)",
        "Participants in the primary trial will receive a total of 12 cycles (28 days) of the intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00550771",
        "e6a4e9a6-56b8-4a30-9743-eb02688c090f",
        "e6a4e9a6-56b8-4a30-9743-eb02688c090f_b",
        "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm",
        "Patients with node-positive T2 N2 M0 breast cancer will be eligible for the primary trial, as will patients with node-negative breast cancer and a tumor diameter of 1.5 cm",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00550771",
        "e6a4e9a6-56b8-4a30-9743-eb02688c090f",
        "016943fa-57ea-4293-8131-03292ea1836c",
        "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm",
        "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00550771",
        "016943fa-57ea-4293-8131-03292ea1836c",
        "e6a4e9a6-56b8-4a30-9743-eb02688c090f",
        "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm",
        "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00550771",
        "016943fa-57ea-4293-8131-03292ea1836c",
        "016943fa-57ea-4293-8131-03292ea1836c_b",
        "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm",
        "Patients with node-positive T2 N2 M0 breast cancer will be eligible for the primary trial, as will patients with node-negative breast cancer and tumors greater than 2 cm in diameter",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00240071",
        "82a3e542-f784-44d7-90f6-34d7e969283c",
        "82a3e542-f784-44d7-90f6-34d7e969283c_b",
        "the primary trial participants receive more than one type of medication during the study",
        "The primary trial participant received more than one medication during the study",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00240071",
        "82a3e542-f784-44d7-90f6-34d7e969283c",
        "045ad91e-44fa-42cc-ac22-a7aab26a9009",
        "the primary trial participants receive more than one type of medication during the study",
        "the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00240071",
        "045ad91e-44fa-42cc-ac22-a7aab26a9009",
        "82a3e542-f784-44d7-90f6-34d7e969283c",
        "the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention",
        "the primary trial participants receive more than one type of medication during the study",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00240071",
        "045ad91e-44fa-42cc-ac22-a7aab26a9009",
        "045ad91e-44fa-42cc-ac22-a7aab26a9009_b",
        "the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention",
        "As part of the intervention, the primary trial participants received Avastin, bevacizumab, and radiation therapy",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01852032_NCT01830933",
        "fb360514-14be-45ab-8b74-ea5a7eb181d7",
        "fb360514-14be-45ab-8b74-ea5a7eb181d7_b",
        "the primary trial and the secondary trial do not report adverse events",
        "Primary and secondary trials did not report adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01852032_NCT01830933",
        "fb360514-14be-45ab-8b74-ea5a7eb181d7",
        "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d",
        "the primary trial and the secondary trial do not report adverse events",
        "the primary trial and the secondary trial report the same types of adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01852032_NCT01830933",
        "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d",
        "fb360514-14be-45ab-8b74-ea5a7eb181d7",
        "the primary trial and the secondary trial report the same types of adverse events",
        "the primary trial and the secondary trial do not report adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01852032_NCT01830933",
        "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d",
        "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d_b",
        "the primary trial and the secondary trial report the same types of adverse events",
        "Primary and secondary trials reported the same type of adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01125566",
        "7137dec6-5c98-4156-8035-7bbaaf0b649d",
        "7137dec6-5c98-4156-8035-7bbaaf0b649d_b",
        "ECOG score < 2 is necessary to be eligible for the primary trial",
        "ECOG score < 2 to be eligible for primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01125566",
        "7137dec6-5c98-4156-8035-7bbaaf0b649d",
        "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41",
        "ECOG score < 2 is necessary to be eligible for the primary trial",
        "ECOG score > 2 is necessary to be eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01125566",
        "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41",
        "7137dec6-5c98-4156-8035-7bbaaf0b649d",
        "ECOG score > 2 is necessary to be eligible for the primary trial",
        "ECOG score < 2 is necessary to be eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01125566",
        "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41",
        "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41_b",
        "ECOG score > 2 is necessary to be eligible for the primary trial",
        "ECOG score > 2 to be eligible for primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00063570",
        "015dd869-db90-45a9-a951-9dc7dc2b2e01",
        "015dd869-db90-45a9-a951-9dc7dc2b2e01_b",
        "patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial",
        "Patients with a malignant brain tumor or colon cancer diagnosis are eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00063570",
        "015dd869-db90-45a9-a951-9dc7dc2b2e01",
        "62e449ad-16b3-479d-94a5-ffc435b5e99c",
        "patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial",
        "patients with a Malignant brain tumour diagnosis are excluded from the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00063570",
        "62e449ad-16b3-479d-94a5-ffc435b5e99c",
        "015dd869-db90-45a9-a951-9dc7dc2b2e01",
        "patients with a Malignant brain tumour diagnosis are excluded from the primary trial",
        "patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00063570",
        "62e449ad-16b3-479d-94a5-ffc435b5e99c",
        "62e449ad-16b3-479d-94a5-ffc435b5e99c_b",
        "patients with a Malignant brain tumour diagnosis are excluded from the primary trial",
        "Patients with tumors were excluded from the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00820170_NCT00263588",
        "3a4003f6-ff1c-43d8-be48-f767266b2cf5",
        "3a4003f6-ff1c-43d8-be48-f767266b2cf5_b",
        "the secondary trial and the primary trial do not have the same inclusion and exclusion conditions",
        "The second trial does not have the same inclusion and exclusion criteria as the first trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00820170_NCT00263588",
        "3a4003f6-ff1c-43d8-be48-f767266b2cf5",
        "a0065d58-e03b-4dd0-9c81-cbbf651a6d45",
        "the secondary trial and the primary trial do not have the same inclusion and exclusion conditions",
        "any patient eligible for the secondary trial will also be eligible for the primary trial ",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00820170_NCT00263588",
        "a0065d58-e03b-4dd0-9c81-cbbf651a6d45",
        "3a4003f6-ff1c-43d8-be48-f767266b2cf5",
        "any patient eligible for the secondary trial will also be eligible for the primary trial ",
        "the secondary trial and the primary trial do not have the same inclusion and exclusion conditions",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00820170_NCT00263588",
        "a0065d58-e03b-4dd0-9c81-cbbf651a6d45",
        "a0065d58-e03b-4dd0-9c81-cbbf651a6d45_b",
        "any patient eligible for the secondary trial will also be eligible for the primary trial ",
        "Any patient eligible for the secondary trial will also be eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00450723_NCT00290758",
        "f3cb9150-32c6-4877-9a87-4fac45a24948",
        "f3cb9150-32c6-4877-9a87-4fac45a24948_b",
        "Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial",
        "Between the secondary trial and the primary trial, all documented cases of musculoskeletal adverse events occurred in cohort 2 of the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00450723_NCT00290758",
        "f3cb9150-32c6-4877-9a87-4fac45a24948",
        "f04d9695-81b8-4d70-877b-59caddf901bd",
        "Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial",
        "Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00450723_NCT00290758",
        "f04d9695-81b8-4d70-877b-59caddf901bd",
        "f3cb9150-32c6-4877-9a87-4fac45a24948",
        "Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial",
        "Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00450723_NCT00290758",
        "f04d9695-81b8-4d70-877b-59caddf901bd",
        "f04d9695-81b8-4d70-877b-59caddf901bd_b",
        "Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial",
        "Between the secondary trial and the primary trial, all documented cases of dyspnea occurred in cohort 1 of the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00733408",
        "9d8b26d6-d574-4717-88b6-77458bc683f3",
        "9d8b26d6-d574-4717-88b6-77458bc683f3_b",
        "Syncope was the most common adverse event recorded in the primary trial",
        "Syncope was the most common adverse event recorded in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00733408",
        "9d8b26d6-d574-4717-88b6-77458bc683f3",
        "4dfff980-6a2b-4f01-9194-6ec831d6fed7",
        "Syncope was the most common adverse event recorded in the primary trial",
        "Infections were the most common adverse events recorded in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00733408",
        "4dfff980-6a2b-4f01-9194-6ec831d6fed7",
        "9d8b26d6-d574-4717-88b6-77458bc683f3",
        "Infections were the most common adverse events recorded in the primary trial",
        "Syncope was the most common adverse event recorded in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00733408",
        "4dfff980-6a2b-4f01-9194-6ec831d6fed7",
        "4dfff980-6a2b-4f01-9194-6ec831d6fed7_b",
        "Infections were the most common adverse events recorded in the primary trial",
        "Infection was the most common adverse event recorded in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01572727_NCT00328783",
        "51be7c95-8da4-419c-950c-91ebdd2c3fe5",
        "51be7c95-8da4-419c-950c-91ebdd2c3fe5_b",
        "All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial",
        "All patients in the primary trial received a higher dose of BKM120 than patients in the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01572727_NCT00328783",
        "51be7c95-8da4-419c-950c-91ebdd2c3fe5",
        "3ba42f68-a643-4d10-afd0-cbb358d05a6f",
        "All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial",
        "All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01572727_NCT00328783",
        "3ba42f68-a643-4d10-afd0-cbb358d05a6f",
        "51be7c95-8da4-419c-950c-91ebdd2c3fe5",
        "All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial",
        "All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01572727_NCT00328783",
        "3ba42f68-a643-4d10-afd0-cbb358d05a6f",
        "3ba42f68-a643-4d10-afd0-cbb358d05a6f_b",
        "All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial",
        "All patients in the primary trial received higher doses of paclitaxel compared to patients in the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00121134_NCT03098550",
        "07042b0f-d422-49c3-8d53-81319927a4b3",
        "07042b0f-d422-49c3-8d53-81319927a4b3_b",
        "all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        "All participants in the primary trial had histologically or cytologically confirmed stage 2 or 3 invasive breast cancer, no specific cancer stage was required for entry into the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00121134_NCT03098550",
        "07042b0f-d422-49c3-8d53-81319927a4b3",
        "7f3fe97e-68ee-470f-b06e-21cdddb67aa8",
        "all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        "all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00121134_NCT03098550",
        "7f3fe97e-68ee-470f-b06e-21cdddb67aa8",
        "07042b0f-d422-49c3-8d53-81319927a4b3",
        "all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        "all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00121134_NCT03098550",
        "7f3fe97e-68ee-470f-b06e-21cdddb67aa8",
        "7f3fe97e-68ee-470f-b06e-21cdddb67aa8_b",
        "all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        "All participants in the primary trial had stage 3 cytology-confirmed invasive breast cancer, no specific cancer stage was required for entry into the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00570921",
        "32361e21-ee57-4c34-9390-833ba5048a10",
        "32361e21-ee57-4c34-9390-833ba5048a10_b",
        "the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally",
        "primary trial participant fulvestrant intramuscularly ( into the deltoid muscle) and everolimus orally",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00570921",
        "32361e21-ee57-4c34-9390-833ba5048a10",
        "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc",
        "the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally",
        "the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00570921",
        "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc",
        "32361e21-ee57-4c34-9390-833ba5048a10",
        "the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally",
        "the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00570921",
        "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc",
        "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc_b",
        "the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally",
        "primary trial participants fulvestrant intramuscularly and everolimus orally",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00503750_NCT00005879",
        "dca4c9f7-bb2a-4f73-b390-93b7ced87c73",
        "dca4c9f7-bb2a-4f73-b390-93b7ced87c73_b",
        "The results from the secondary trial and the primary trial are non-comparable",
        "The results of the second test and the first test are not comparable",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00503750_NCT00005879",
        "dca4c9f7-bb2a-4f73-b390-93b7ced87c73",
        "7d52734c-0801-413d-9ae2-d190b972cde5",
        "The results from the secondary trial and the primary trial are non-comparable",
        "The results from the secondary trial and the primary trial can be compared by changing the units from days to months",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00503750_NCT00005879",
        "7d52734c-0801-413d-9ae2-d190b972cde5",
        "dca4c9f7-bb2a-4f73-b390-93b7ced87c73",
        "The results from the secondary trial and the primary trial can be compared by changing the units from days to months",
        "The results from the secondary trial and the primary trial are non-comparable",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00503750_NCT00005879",
        "7d52734c-0801-413d-9ae2-d190b972cde5",
        "7d52734c-0801-413d-9ae2-d190b972cde5_b",
        "The results from the secondary trial and the primary trial can be compared by changing the units from days to months",
        "The results of the second run and the first run can be compared by changing the units from days to months",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00290732_NCT00232505",
        "e7604382-09cd-43b4-998f-a51b33f25c5a",
        "e7604382-09cd-43b4-998f-a51b33f25c5a_b",
        "the primary trial and the secondary trial participants do not receive any medication orally",
        "Primary and secondary trial participants did not receive any oral medications",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00290732_NCT00232505",
        "e7604382-09cd-43b4-998f-a51b33f25c5a",
        "7edba90d-076d-4f55-b9d6-a1765ceb48bd",
        "the primary trial and the secondary trial participants do not receive any medication orally",
        "the primary trial and the secondary trial participants do not receive any medication by IV",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00290732_NCT00232505",
        "7edba90d-076d-4f55-b9d6-a1765ceb48bd",
        "e7604382-09cd-43b4-998f-a51b33f25c5a",
        "the primary trial and the secondary trial participants do not receive any medication by IV",
        "the primary trial and the secondary trial participants do not receive any medication orally",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00290732_NCT00232505",
        "7edba90d-076d-4f55-b9d6-a1765ceb48bd",
        "7edba90d-076d-4f55-b9d6-a1765ceb48bd_b",
        "the primary trial and the secondary trial participants do not receive any medication by IV",
        "Participants in the primary and secondary trials did not receive any medication by intravenous injection",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00193037",
        "75affd49-4905-4d43-9a5c-ef795281bac4",
        "75affd49-4905-4d43-9a5c-ef795281bac4_b",
        "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.",
        "Neither intervention in the primary trial resulted in an objective benefit in more than 40% of patients.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00193037",
        "75affd49-4905-4d43-9a5c-ef795281bac4",
        "74e376d7-5713-43f3-93f1-9608059c9547",
        "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.",
        "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00193037",
        "74e376d7-5713-43f3-93f1-9608059c9547",
        "75affd49-4905-4d43-9a5c-ef795281bac4",
        "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications",
        "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00193037",
        "74e376d7-5713-43f3-93f1-9608059c9547",
        "74e376d7-5713-43f3-93f1-9608059c9547_b",
        "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications",
        "Neither intervention produced objective benefit in more than 40% of patients in the primary trial, and in fact more than 86% of patients treated with docetaxel had fatal complications with subsequent liposomal doxorubicin intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00357110",
        "f114846e-79d8-4712-add0-bb34b65d418f",
        "f114846e-79d8-4712-add0-bb34b65d418f_b",
        "there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.",
        "Six deaths were recorded in cohort 1 and 7 deaths in cohort 2 of the primary trial.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00357110",
        "f114846e-79d8-4712-add0-bb34b65d418f",
        "751fd763-89fa-4d52-8bda-f09b490a5e78",
        "there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.",
        "there were no recorded deaths in the primary trial cohorts.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00357110",
        "751fd763-89fa-4d52-8bda-f09b490a5e78",
        "f114846e-79d8-4712-add0-bb34b65d418f",
        "there were no recorded deaths in the primary trial cohorts.",
        "there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00357110",
        "751fd763-89fa-4d52-8bda-f09b490a5e78",
        "751fd763-89fa-4d52-8bda-f09b490a5e78_b",
        "there were no recorded deaths in the primary trial cohorts.",
        "No deaths were recorded in the primary trial cohort.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01416389",
        "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe",
        "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe_b",
        "the primary trial reports the changes in the number of lesions for patients in its cohorts.",
        "Major trials reported changes in the number of lesions in patients in their cohorts.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01416389",
        "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe",
        "7cde9a22-a91f-4feb-892d-7cbd35f96a27",
        "the primary trial reports the changes in the number of lesions for patients in its cohorts.",
        "the primary trial reports the changes in tumor size for patients in its cohorts.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01416389",
        "7cde9a22-a91f-4feb-892d-7cbd35f96a27",
        "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe",
        "the primary trial reports the changes in tumor size for patients in its cohorts.",
        "the primary trial reports the changes in the number of lesions for patients in its cohorts.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01416389",
        "7cde9a22-a91f-4feb-892d-7cbd35f96a27",
        "7cde9a22-a91f-4feb-892d-7cbd35f96a27_b",
        "the primary trial reports the changes in tumor size for patients in its cohorts.",
        "Major trials reported changes in tumor size among patients in their cohorts.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00876395",
        "b1d28450-fc7d-496a-9c7c-bf711b28f8e4",
        "b1d28450-fc7d-496a-9c7c-bf711b28f8e4_b",
        "all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        "All pregnant patients in the primary trial were treated with endocrine therapy for breast cancer",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00876395",
        "b1d28450-fc7d-496a-9c7c-bf711b28f8e4",
        "6d621974-c719-46df-8a50-d94e49583e33",
        "all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        "all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00876395",
        "6d621974-c719-46df-8a50-d94e49583e33",
        "b1d28450-fc7d-496a-9c7c-bf711b28f8e4",
        "all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        "all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00876395",
        "6d621974-c719-46df-8a50-d94e49583e33",
        "6d621974-c719-46df-8a50-d94e49583e33_b",
        "all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        "All patients in the primary trial were treated with endocrine therapy for breast cancer",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00331630",
        "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3",
        "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3_b",
        "no cardiac or neural adverse events were recorded in the primary trial",
        "No cardiac or neurological adverse events were recorded in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00331630",
        "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3",
        "553f00ea-5197-4233-b1e0-e5727856b599",
        "no cardiac or neural adverse events were recorded in the primary trial",
        "no cardiac or bowel-related adverse events were recorded in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00331630",
        "553f00ea-5197-4233-b1e0-e5727856b599",
        "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3",
        "no cardiac or bowel-related adverse events were recorded in the primary trial",
        "no cardiac or neural adverse events were recorded in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00331630",
        "553f00ea-5197-4233-b1e0-e5727856b599",
        "553f00ea-5197-4233-b1e0-e5727856b599_b",
        "no cardiac or bowel-related adverse events were recorded in the primary trial",
        "No cardiac or bowel-related adverse events were recorded in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00005879",
        "e4aeb013-7713-4b73-acbd-f8379cc6a494",
        "e4aeb013-7713-4b73-acbd-f8379cc6a494_b",
        "there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        "In cohort 2 of the primary trial, the percentage of patients with disc herniation was higher than in cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00005879",
        "e4aeb013-7713-4b73-acbd-f8379cc6a494",
        "ce8464bd-951e-44aa-97d9-10b917b055ce",
        "there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        "there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00005879",
        "ce8464bd-951e-44aa-97d9-10b917b055ce",
        "e4aeb013-7713-4b73-acbd-f8379cc6a494",
        "there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        "there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00005879",
        "ce8464bd-951e-44aa-97d9-10b917b055ce",
        "ce8464bd-951e-44aa-97d9-10b917b055ce_b",
        "there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        "The percentage of patients with disc herniation was significantly higher in cohort 2 of the primary trial than in cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01808573",
        "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3",
        "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3_b",
        "All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months",
        "All patients in the primary trial cohort 1 had a PFS of more than 7 months, with a maximum PFS of less than 10 months",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01808573",
        "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3",
        "b9e29ea8-6847-40d4-b5c3-81c496101695",
        "All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months",
        "All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01808573",
        "b9e29ea8-6847-40d4-b5c3-81c496101695",
        "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3",
        "All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months",
        "All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01808573",
        "b9e29ea8-6847-40d4-b5c3-81c496101695",
        "b9e29ea8-6847-40d4-b5c3-81c496101695_b",
        "All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months",
        "All patients in the primary trial cohort 1 had a PFS of more than 8.8 months, with the highest PFS of less than 10 months",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00093795",
        "2729a321-709b-4392-9604-dd7237bedb17",
        "2729a321-709b-4392-9604-dd7237bedb17_b",
        "the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.",
        "Most participants in the primary trial cohorts 1 and 2 achieved 5-year disease-free survival.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00093795",
        "2729a321-709b-4392-9604-dd7237bedb17",
        "0ea29bd5-20be-40ea-8ad7-705d283d1d48",
        "the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.",
        "the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00093795",
        "0ea29bd5-20be-40ea-8ad7-705d283d1d48",
        "2729a321-709b-4392-9604-dd7237bedb17",
        "the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer",
        "the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00093795",
        "0ea29bd5-20be-40ea-8ad7-705d283d1d48",
        "0ea29bd5-20be-40ea-8ad7-705d283d1d48_b",
        "the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer",
        "The majority of participants in the primary trial cohort 1 and cohort 2 had a disease recurrence, contralateral breast cancer, second primary cancer, death from any cause before recurrence, or a second primary cancer",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00617539",
        "b9491012-49ba-4eb1-8230-1966f54ea012",
        "b9491012-49ba-4eb1-8230-1966f54ea012_b",
        "Patients with Extracranial metastases can be eligible for the primary trial",
        "Patients with extracranial metastases eligible for primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00617539",
        "b9491012-49ba-4eb1-8230-1966f54ea012",
        "a9bb6de9-c6f8-4c99-81cd-f101cbaab387",
        "Patients with Extracranial metastases can be eligible for the primary trial",
        "Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00617539",
        "a9bb6de9-c6f8-4c99-81cd-f101cbaab387",
        "b9491012-49ba-4eb1-8230-1966f54ea012",
        "Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial",
        "Patients with Extracranial metastases can be eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00617539",
        "a9bb6de9-c6f8-4c99-81cd-f101cbaab387",
        "a9bb6de9-c6f8-4c99-81cd-f101cbaab387_b",
        "Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial",
        "Patients must have no radiographically confirmed brain metastases to be eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01216176_NCT00325234",
        "7271e0db-bb82-423f-ad95-5ffa84fab97e",
        "7271e0db-bb82-423f-ad95-5ffa84fab97e_b",
        "There are more cases of Urosepsis in the primary trial than in the secondary trial",
        "More urosepsis cases in primary trials than secondary trials",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01216176_NCT00325234",
        "7271e0db-bb82-423f-ad95-5ffa84fab97e",
        "9c033072-5f94-4d79-af47-126d531f0d6e",
        "There are more cases of Urosepsis in the primary trial than in the secondary trial",
        "There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01216176_NCT00325234",
        "9c033072-5f94-4d79-af47-126d531f0d6e",
        "7271e0db-bb82-423f-ad95-5ffa84fab97e",
        "There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial",
        "There are more cases of Urosepsis in the primary trial than in the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01216176_NCT00325234",
        "9c033072-5f94-4d79-af47-126d531f0d6e",
        "9c033072-5f94-4d79-af47-126d531f0d6e_b",
        "There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial",
        "more cases Head and catheter-related infections in the primary trial compared with the secondary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01011946_NCT00066573",
        "6402e13a-7cfb-4774-b7f9-80ecb79fda2a",
        "6402e13a-7cfb-4774-b7f9-80ecb79fda2a_b",
        "the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.",
        "Participants in the primary trial were not taking any oral medications, while patients in the secondary trial received only oral therapy.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01011946_NCT00066573",
        "6402e13a-7cfb-4774-b7f9-80ecb79fda2a",
        "8ddf8b88-6e06-4c71-9e28-45f73a637af0",
        "the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.",
        "the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01011946_NCT00066573",
        "8ddf8b88-6e06-4c71-9e28-45f73a637af0",
        "6402e13a-7cfb-4774-b7f9-80ecb79fda2a",
        "the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.",
        "the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01011946_NCT00066573",
        "8ddf8b88-6e06-4c71-9e28-45f73a637af0",
        "8ddf8b88-6e06-4c71-9e28-45f73a637af0_b",
        "the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.",
        "Participants in the primary trial received oral and topical medication, while patients in the secondary trial received oral therapy only.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01307891",
        "734423d5-4b47-4448-ab98-811015d626f0",
        "734423d5-4b47-4448-ab98-811015d626f0_b",
        "There were multiple patients which suffered Neutropenia in both cohorts of the primary trial",
        "Multiple patients with neutropenia in both cohorts of primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01307891",
        "734423d5-4b47-4448-ab98-811015d626f0",
        "a9907a2e-254a-45ca-af50-3e44fd2f7af3",
        "There were multiple patients which suffered Neutropenia in both cohorts of the primary trial",
        "There was one case of  Neutropenia in both cohorts of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01307891",
        "a9907a2e-254a-45ca-af50-3e44fd2f7af3",
        "734423d5-4b47-4448-ab98-811015d626f0",
        "There was one case of  Neutropenia in both cohorts of the primary trial",
        "There were multiple patients which suffered Neutropenia in both cohorts of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01307891",
        "a9907a2e-254a-45ca-af50-3e44fd2f7af3",
        "a9907a2e-254a-45ca-af50-3e44fd2f7af3_b",
        "There was one case of  Neutropenia in both cohorts of the primary trial",
        "neutropenia in both cohorts of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00612560_NCT01216176",
        "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd",
        "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd_b",
        "All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole",
        "All primary trial participants took anastrozole in pill form , but no one in the secondary trial received any anastrozole",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00612560_NCT01216176",
        "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd",
        "b0046821-ba27-4a90-8869-cb708b843aa4",
        "All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole",
        "All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00612560_NCT01216176",
        "b0046821-ba27-4a90-8869-cb708b843aa4",
        "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd",
        "All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed",
        "All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00612560_NCT01216176",
        "b0046821-ba27-4a90-8869-cb708b843aa4",
        "b0046821-ba27-4a90-8869-cb708b843aa4_b",
        "All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed",
        "All primary trial participants were given flaxseed, but no one in the secondary trial was given any flaxseed",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00572728",
        "32ed503c-1cfd-44f6-b8bb-23d9d175d73d",
        "32ed503c-1cfd-44f6-b8bb-23d9d175d73d_b",
        "Patients must be able to undergo a PET scan to participate in the primary trial",
        "Patients must be able to undergo PET scans to participate in primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00572728",
        "32ed503c-1cfd-44f6-b8bb-23d9d175d73d",
        "62be4676-099f-4c42-8029-773af8fde6f7",
        "Patients must be able to undergo a PET scan to participate in the primary trial",
        "Patients must be bedbound or severaly disabled to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00572728",
        "62be4676-099f-4c42-8029-773af8fde6f7",
        "32ed503c-1cfd-44f6-b8bb-23d9d175d73d",
        "Patients must be bedbound or severaly disabled to participate in the primary trial",
        "Patients must be able to undergo a PET scan to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00572728",
        "62be4676-099f-4c42-8029-773af8fde6f7",
        "62be4676-099f-4c42-8029-773af8fde6f7_b",
        "Patients must be bedbound or severaly disabled to participate in the primary trial",
        "Patients must be bedridden or have several disabilities to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00606931",
        "175044aa-72b1-405d-8506-30002f5098e4",
        "175044aa-72b1-405d-8506-30002f5098e4_b",
        "There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study",
        "The Adverse Events section of the primary trial describes the number of patients who experienced hypotension, bleeding and bradycardia while participating in the study",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00606931",
        "175044aa-72b1-405d-8506-30002f5098e4",
        "21611c2a-e6eb-4012-a209-9b6781e1f260",
        "There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study",
        "There is no adverse events section in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00606931",
        "21611c2a-e6eb-4012-a209-9b6781e1f260",
        "175044aa-72b1-405d-8506-30002f5098e4",
        "There is no adverse events section in the primary trial",
        "There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00606931",
        "21611c2a-e6eb-4012-a209-9b6781e1f260",
        "21611c2a-e6eb-4012-a209-9b6781e1f260_b",
        "There is no adverse events section in the primary trial",
        "No adverse events component in primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01830933_NCT00852930",
        "06f798d1-2956-4903-83e9-58a41fa425f7",
        "06f798d1-2956-4903-83e9-58a41fa425f7_b",
        "the primary trial and the secondary trial do not record any cardiac or infection related adverse events",
        "The primary and secondary trials did not record any cardiac or infection-related adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01830933_NCT00852930",
        "06f798d1-2956-4903-83e9-58a41fa425f7",
        "c2217d42-e90c-4ffe-b084-e653b9ace4d5",
        "the primary trial and the secondary trial do not record any cardiac or infection related adverse events",
        "the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01830933_NCT00852930",
        "c2217d42-e90c-4ffe-b084-e653b9ace4d5",
        "06f798d1-2956-4903-83e9-58a41fa425f7",
        "the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy",
        "the primary trial and the secondary trial do not record any cardiac or infection related adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01830933_NCT00852930",
        "c2217d42-e90c-4ffe-b084-e653b9ace4d5",
        "c2217d42-e90c-4ffe-b084-e653b9ace4d5_b",
        "the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy",
        "The primary and secondary trials did not document any cardiac or infection-related adverse events, but they both documented several cases of seizures",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00009945",
        "8648c7df-582a-42a9-9330-414b2430ac56",
        "8648c7df-582a-42a9-9330-414b2430ac56_b",
        "none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events",
        "None of the individual adverse events in the primary trial affected more than 100 patients and fewer than 30 patients in total had adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00009945",
        "8648c7df-582a-42a9-9330-414b2430ac56",
        "1314146f-2869-4525-8034-7f732d238385",
        "none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events",
        "none of the individual adverse events in the primary trial affect more than 100 patients.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00009945",
        "1314146f-2869-4525-8034-7f732d238385",
        "8648c7df-582a-42a9-9330-414b2430ac56",
        "none of the individual adverse events in the primary trial affect more than 100 patients.",
        "none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00009945",
        "1314146f-2869-4525-8034-7f732d238385",
        "1314146f-2869-4525-8034-7f732d238385_b",
        "none of the individual adverse events in the primary trial affect more than 100 patients.",
        "No single adverse event in the primary trial affected more than 100 patients.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01596751",
        "89f610a7-9e81-43a4-8c1e-5503233b2be1",
        "89f610a7-9e81-43a4-8c1e-5503233b2be1_b",
        "Breast cancer patients must have documented stable disease to participate in the primary trial",
        "Breast cancer patients must demonstrate stable disease to enroll in primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01596751",
        "89f610a7-9e81-43a4-8c1e-5503233b2be1",
        "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8",
        "Breast cancer patients must have documented stable disease to participate in the primary trial",
        "Breast cancer patients must have documented progressive disease to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01596751",
        "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8",
        "89f610a7-9e81-43a4-8c1e-5503233b2be1",
        "Breast cancer patients must have documented progressive disease to participate in the primary trial",
        "Breast cancer patients must have documented stable disease to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01596751",
        "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8",
        "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8_b",
        "Breast cancer patients must have documented progressive disease to participate in the primary trial",
        "Breast cancer patients must have documented progressive disease to enroll in primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00374322",
        "e147796d-2edd-42d1-ac53-300fb8bd5eb6",
        "e147796d-2edd-42d1-ac53-300fb8bd5eb6_b",
        "80% of patients in the primary trial received a placebo intervention",
        "80% of patients in primary trial received placebo intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00374322",
        "e147796d-2edd-42d1-ac53-300fb8bd5eb6",
        "c40fdf91-9f81-454a-bba9-ec5c950cef6e",
        "80% of patients in the primary trial received a placebo intervention",
        "One patient cohort in the primary trial received a placebo intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00374322",
        "c40fdf91-9f81-454a-bba9-ec5c950cef6e",
        "e147796d-2edd-42d1-ac53-300fb8bd5eb6",
        "One patient cohort in the primary trial received a placebo intervention",
        "80% of patients in the primary trial received a placebo intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00374322",
        "c40fdf91-9f81-454a-bba9-ec5c950cef6e",
        "c40fdf91-9f81-454a-bba9-ec5c950cef6e_b",
        "One patient cohort in the primary trial received a placebo intervention",
        "A group of patients in the primary trial received a placebo intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02445586",
        "6b33b4ae-36f2-4a53-a954-6f246f6e023d",
        "6b33b4ae-36f2-4a53-a954-6f246f6e023d_b",
        "Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)",
        "Patients wishing to participate in the primary trial must have a known and documented HER2+ status and a LVEF of at least 50% (%)",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02445586",
        "6b33b4ae-36f2-4a53-a954-6f246f6e023d",
        "9abb10d7-496e-44fd-915d-d86aedf6c9b6",
        "Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)",
        "Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%)",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02445586",
        "9abb10d7-496e-44fd-915d-d86aedf6c9b6",
        "6b33b4ae-36f2-4a53-a954-6f246f6e023d",
        "Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%)",
        "Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02445586",
        "9abb10d7-496e-44fd-915d-d86aedf6c9b6",
        "9abb10d7-496e-44fd-915d-d86aedf6c9b6_b",
        "Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%)",
        "Patients wishing to participate in the primary trial must have known and documented TNBC status and a LVEF of at least 50% (%)",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00325234_NCT00274469",
        "06fad978-1dc3-46f5-b45f-5ac6577f28b9",
        "06fad978-1dc3-46f5-b45f-5ac6577f28b9_b",
        "Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial",
        "Patients must be female and have been diagnosed with advanced colon cancer to be eligible for the second trial and the first trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00325234_NCT00274469",
        "06fad978-1dc3-46f5-b45f-5ac6577f28b9",
        "68379456-775b-463b-bfdb-d8aa42c9124b",
        "Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial",
        "Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00325234_NCT00274469",
        "68379456-775b-463b-bfdb-d8aa42c9124b",
        "06fad978-1dc3-46f5-b45f-5ac6577f28b9",
        "Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial",
        "Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00325234_NCT00274469",
        "68379456-775b-463b-bfdb-d8aa42c9124b",
        "68379456-775b-463b-bfdb-d8aa42c9124b_b",
        "Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial",
        "Patients must be female and have been diagnosed with advanced breast cancer to be eligible for both the second trial and the first trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02658734",
        "878c09e7-3fd9-404e-921e-5b549e9578fb",
        "878c09e7-3fd9-404e-921e-5b549e9578fb_b",
        "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.",
        "Most patients in the primary trial experienced grade 1 adverse events, with grade 4 being the least common severity.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02658734",
        "878c09e7-3fd9-404e-921e-5b549e9578fb",
        "40f699a1-fbc6-40de-8e80-85b28f71632f",
        "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.",
        "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02658734",
        "40f699a1-fbc6-40de-8e80-85b28f71632f",
        "878c09e7-3fd9-404e-921e-5b549e9578fb",
        "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients.",
        "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02658734",
        "40f699a1-fbc6-40de-8e80-85b28f71632f",
        "40f699a1-fbc6-40de-8e80-85b28f71632f_b",
        "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients.",
        "Most patients in the primary trial experienced grade 1 adverse events, the least common being grade 5 in severity, affecting only 8/70 patients.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02131064",
        "3a0c517d-9b9a-4497-9675-50ff12cd02b7",
        "3a0c517d-9b9a-4497-9675-50ff12cd02b7_b",
        "in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain",
        "In cohort 1 of the primary trial, there were more cases of left ventricular dysfunction than abdominal pain",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02131064",
        "3a0c517d-9b9a-4497-9675-50ff12cd02b7",
        "1329dec6-fb2c-4219-9db6-3fef9d94b316",
        "in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain",
        "in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02131064",
        "1329dec6-fb2c-4219-9db6-3fef9d94b316",
        "3a0c517d-9b9a-4497-9675-50ff12cd02b7",
        "in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain",
        "in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02131064",
        "1329dec6-fb2c-4219-9db6-3fef9d94b316",
        "1329dec6-fb2c-4219-9db6-3fef9d94b316_b",
        "in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain",
        "In cohort 1 of the primary trial, there were 10 more cases of left ventricular dysfunction than abdominal pain",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT03012477_NCT02419807",
        "8460a212-8054-4bd2-b4e6-af1d137a2f79",
        "8460a212-8054-4bd2-b4e6-af1d137a2f79_b",
        "the primary trial and the secondary trial report their results using different units of measure",
        "Primary and secondary trials report their results using different units of measurement",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT03012477_NCT02419807",
        "8460a212-8054-4bd2-b4e6-af1d137a2f79",
        "0e609fad-9a28-4fb6-90b6-32a731e3b02c",
        "the primary trial and the secondary trial report their results using different units of measure",
        "the primary trial and the secondary trial report their results as perecentages but use different units of measure.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT03012477_NCT02419807",
        "0e609fad-9a28-4fb6-90b6-32a731e3b02c",
        "8460a212-8054-4bd2-b4e6-af1d137a2f79",
        "the primary trial and the secondary trial report their results as perecentages but use different units of measure.",
        "the primary trial and the secondary trial report their results using different units of measure",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT03012477_NCT02419807",
        "0e609fad-9a28-4fb6-90b6-32a731e3b02c",
        "0e609fad-9a28-4fb6-90b6-32a731e3b02c_b",
        "the primary trial and the secondary trial report their results as perecentages but use different units of measure.",
        "Percentage reports the result, but uses a different unit of measurement.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00477464",
        "a3390ae6-d41d-4dc7-899e-de9534adfd6b",
        "a3390ae6-d41d-4dc7-899e-de9534adfd6b_b",
        "the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib",
        "Primary trial participants received significantly higher doses of capecitabine than lapatinib",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00477464",
        "a3390ae6-d41d-4dc7-899e-de9534adfd6b",
        "a52b2d4f-0b06-4960-a9c3-88cb92df0980",
        "the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib",
        "the primary trial participants receive Capecitabine less often than they receive Lapatinib",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00477464",
        "a52b2d4f-0b06-4960-a9c3-88cb92df0980",
        "a3390ae6-d41d-4dc7-899e-de9534adfd6b",
        "the primary trial participants receive Capecitabine less often than they receive Lapatinib",
        "the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00477464",
        "a52b2d4f-0b06-4960-a9c3-88cb92df0980",
        "a52b2d4f-0b06-4960-a9c3-88cb92df0980_b",
        "the primary trial participants receive Capecitabine less often than they receive Lapatinib",
        "Primary trial participants received capecitabine less frequently than lapatinib",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00445458",
        "17bbea92-8f92-41f3-9b9d-cf6e62cf6798",
        "17bbea92-8f92-41f3-9b9d-cf6e62cf6798_b",
        "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.",
        "of patients treated with neratinib in combination with paclitaxel who experienced side effects severe enough to prevent escalation of the dose or level of this treatment.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00445458",
        "17bbea92-8f92-41f3-9b9d-cf6e62cf6798",
        "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2",
        "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.",
        "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00445458",
        "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2",
        "17bbea92-8f92-41f3-9b9d-cf6e62cf6798",
        "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects",
        "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00445458",
        "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2",
        "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2_b",
        "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects",
        "Percentage of patients receiving neratinib plus paclitaxel with zero side effects",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00633464_NCT01644890",
        "794269ca-e7ec-4a65-ace5-b0f24a8cdc15",
        "794269ca-e7ec-4a65-ace5-b0f24a8cdc15_b",
        "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS",
        "The primary trial measures the percentage of participants in its cohort with an objective response, while the secondary trial measures PFS",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00633464_NCT01644890",
        "794269ca-e7ec-4a65-ace5-b0f24a8cdc15",
        "f42e1874-343a-43ed-bb0c-884509c4793c",
        "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS",
        "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00633464_NCT01644890",
        "f42e1874-343a-43ed-bb0c-884509c4793c",
        "794269ca-e7ec-4a65-ace5-b0f24a8cdc15",
        "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death",
        "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00633464_NCT01644890",
        "f42e1874-343a-43ed-bb0c-884509c4793c",
        "f42e1874-343a-43ed-bb0c-884509c4793c_b",
        "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death",
        "The primary trial measures the percentage of participants in its cohort with an objective response, while the secondary trial measures the number of participants with progressive disease (PD) or death",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00852930_NCT02915744",
        "dc4c57b0-8c75-494e-81b0-3528df85ebff",
        "dc4c57b0-8c75-494e-81b0-3528df85ebff_b",
        "neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts",
        "secondary nor the primary trial recorded overall survival (OS) of patients in its cohort",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00852930_NCT02915744",
        "dc4c57b0-8c75-494e-81b0-3528df85ebff",
        "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1",
        "neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts",
        "the secondary trial and the primary trial do not record the same metrics in their results section",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00852930_NCT02915744",
        "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1",
        "dc4c57b0-8c75-494e-81b0-3528df85ebff",
        "the secondary trial and the primary trial do not record the same metrics in their results section",
        "neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00852930_NCT02915744",
        "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1",
        "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1_b",
        "the secondary trial and the primary trial do not record the same metrics in their results section",
        "Metrics recorded in the results section are different for the second run and the first run",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00305448_NCT00425854",
        "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c",
        "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c_b",
        "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response ",
        "The secondary and primary trials used objective response as an outcome measure for the intervention, but they used different definitions of complete response",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00305448_NCT00425854",
        "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c",
        "402f0dbf-cf67-4425-b300-a0a3df4d59d3",
        "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response ",
        "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. ",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00305448_NCT00425854",
        "402f0dbf-cf67-4425-b300-a0a3df4d59d3",
        "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c",
        "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. ",
        "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response ",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00305448_NCT00425854",
        "402f0dbf-cf67-4425-b300-a0a3df4d59d3",
        "402f0dbf-cf67-4425-b300-a0a3df4d59d3_b",
        "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. ",
        "The secondary and primary trials used objective responses as outcome measures for their interventions.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00754325",
        "251a20d8-2555-4929-9d01-c02311bdc93f",
        "251a20d8-2555-4929-9d01-c02311bdc93f_b",
        "a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1",
        "A higher proportion of patients experienced disease progression or died in cohort 2 of the primary trial compared with cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00754325",
        "251a20d8-2555-4929-9d01-c02311bdc93f",
        "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37",
        "a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1",
        "in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00754325",
        "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37",
        "251a20d8-2555-4929-9d01-c02311bdc93f",
        "in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin",
        "a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00754325",
        "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37",
        "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37_b",
        "in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin",
        "In primary trials, patients treated with fulvestrant were more likely to have disease progression or die than those treated with Herceptin",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00127933",
        "f0273b8c-460d-46fe-9c52-8ff4b08e439b",
        "f0273b8c-460d-46fe-9c52-8ff4b08e439b_b",
        "eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial",
        "eliane is a 56-year-old woman and elizabeth is a 32-year-old woman, both eliane and elizabeth are eligible to participate in the preliminary review",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00127933",
        "f0273b8c-460d-46fe-9c52-8ff4b08e439b",
        "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb",
        "eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial",
        "eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00127933",
        "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb",
        "f0273b8c-460d-46fe-9c52-8ff4b08e439b",
        "eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial",
        "eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00127933",
        "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb",
        "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb_b",
        "eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial",
        "eliane is a 56-year-old woman and alex is a 32-year-old man, both eliane and alex are eligible for the preliminary review",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02244580_NCT03176238",
        "080da381-b5dd-46d3-99c4-18112da153c1",
        "080da381-b5dd-46d3-99c4-18112da153c1_b",
        "There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial",
        "Fewer cases of acute myocardial infarction, cardiorespiratory failure and supraventricular tachycardia in cohort 1 of the secondary trial compared with cohort 2 of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02244580_NCT03176238",
        "080da381-b5dd-46d3-99c4-18112da153c1",
        "5c975af8-6b7f-4a5d-b4a6-257c76763ce9",
        "There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial",
        "There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02244580_NCT03176238",
        "5c975af8-6b7f-4a5d-b4a6-257c76763ce9",
        "080da381-b5dd-46d3-99c4-18112da153c1",
        "There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial",
        "There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02244580_NCT03176238",
        "5c975af8-6b7f-4a5d-b4a6-257c76763ce9",
        "5c975af8-6b7f-4a5d-b4a6-257c76763ce9_b",
        "There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial",
        "More cases of acute myocardial infarction, cardiorespiratory failure, and supraventricular tachycardia occurred in cohort 1 of the secondary trial compared with the entire cohort of patients in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00258960_NCT00121992",
        "c100a7cd-e3a2-4901-a3e0-12336f769c7b",
        "c100a7cd-e3a2-4901-a3e0-12336f769c7b_b",
        "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16",
        "The secondary trial reported 1 case of conjunctivitis, while the primary trial reported 16 cases",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00258960_NCT00121992",
        "c100a7cd-e3a2-4901-a3e0-12336f769c7b",
        "a5617ae4-05a3-42d0-9e14-141de5f8c010",
        "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16",
        "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00258960_NCT00121992",
        "a5617ae4-05a3-42d0-9e14-141de5f8c010",
        "c100a7cd-e3a2-4901-a3e0-12336f769c7b",
        "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any",
        "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00258960_NCT00121992",
        "a5617ae4-05a3-42d0-9e14-141de5f8c010",
        "a5617ae4-05a3-42d0-9e14-141de5f8c010_b",
        "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any",
        "The secondary trial reported 1 case of conjunctivitis whereas the primary trial did not report any",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00376597",
        "b1dd7632-ed92-40a9-9293-bce68619c658",
        "b1dd7632-ed92-40a9-9293-bce68619c658_b",
        "Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible",
        "Patients with stage 4 cancer were excluded from the primary trial, only patients with stage 2 and 3 cancer were eligible",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00376597",
        "b1dd7632-ed92-40a9-9293-bce68619c658",
        "75a65913-5655-4377-b441-ecdd4dd75175",
        "Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible",
        "Patients with stage 4 cancer are excluded from the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00376597",
        "75a65913-5655-4377-b441-ecdd4dd75175",
        "b1dd7632-ed92-40a9-9293-bce68619c658",
        "Patients with stage 4 cancer are excluded from the primary trial",
        "Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00376597",
        "75a65913-5655-4377-b441-ecdd4dd75175",
        "75a65913-5655-4377-b441-ecdd4dd75175_b",
        "Patients with stage 4 cancer are excluded from the primary trial",
        "Patients with stage 4 cancer excluded from primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01042938",
        "4a15ec5e-4904-4f01-a0a2-c51e83c8c070",
        "4a15ec5e-4904-4f01-a0a2-c51e83c8c070_b",
        "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort",
        "Primary trial reports severity of radiation treatment site dermatitis in curcumin C3 complex cohort and placebo cohort",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01042938",
        "4a15ec5e-4904-4f01-a0a2-c51e83c8c070",
        "e62f5a3f-0091-4980-9822-db8f4dc2502a",
        "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort",
        "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01042938",
        "e62f5a3f-0091-4980-9822-db8f4dc2502a",
        "4a15ec5e-4904-4f01-a0a2-c51e83c8c070",
        "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts",
        "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01042938",
        "e62f5a3f-0091-4980-9822-db8f4dc2502a",
        "e62f5a3f-0091-4980-9822-db8f4dc2502a_b",
        "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts",
        "The primary trial reported the severity of radiation treatment site dermatitis in the curcumin C3 complex cohort and the placebo cohort, with no difference in outcomes between the two cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00375427",
        "618a3ae1-b22c-4c35-86a6-190c1b5b5d21",
        "618a3ae1-b22c-4c35-86a6-190c1b5b5d21_b",
        "Patients must have a Life expectancy of at least 1 year to enroll in the primary trial",
        "Patients must have a life expectancy of at least 1 year to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00375427",
        "618a3ae1-b22c-4c35-86a6-190c1b5b5d21",
        "4b97a844-8d52-48bb-8eda-ca205268f016",
        "Patients must have a Life expectancy of at least 1 year to enroll in the primary trial",
        "Patients must have a Life expectancy of 75+ years to enroll in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00375427",
        "4b97a844-8d52-48bb-8eda-ca205268f016",
        "618a3ae1-b22c-4c35-86a6-190c1b5b5d21",
        "Patients must have a Life expectancy of 75+ years to enroll in the primary trial",
        "Patients must have a Life expectancy of at least 1 year to enroll in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00375427",
        "4b97a844-8d52-48bb-8eda-ca205268f016",
        "4b97a844-8d52-48bb-8eda-ca205268f016_b",
        "Patients must have a Life expectancy of 75+ years to enroll in the primary trial",
        "Patients must have a life expectancy of over 75 years to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00290758_NCT02370238",
        "4a41ac73-538a-43e5-b7ce-8c8e2d56286e",
        "4a41ac73-538a-43e5-b7ce-8c8e2d56286e_b",
        "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.",
        "Women currently receiving endocrine therapy were excluded from the secondary and primary trials unless they were receiving adjuvant therapy.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00290758_NCT02370238",
        "4a41ac73-538a-43e5-b7ce-8c8e2d56286e",
        "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb",
        "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.",
        "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00290758_NCT02370238",
        "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb",
        "4a41ac73-538a-43e5-b7ce-8c8e2d56286e",
        "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial",
        "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00290758_NCT02370238",
        "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb",
        "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb_b",
        "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial",
        "Women currently receiving endocrine therapy were excluded from the secondary and primary trials",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00191815",
        "29b2fa29-5a76-4877-95bb-1a8de7973d33",
        "29b2fa29-5a76-4877-95bb-1a8de7973d33_b",
        "Only 6/67 patients in cohort 1 of the primary trial suffered adverse events",
        "Adverse events occurred in only 6/67 patients in cohort 1 of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00191815",
        "29b2fa29-5a76-4877-95bb-1a8de7973d33",
        "8e91e404-086e-4063-8d54-83d1b8ebd969",
        "Only 6/67 patients in cohort 1 of the primary trial suffered adverse events",
        "over 1/6 patients in cohort 1 of the primary trial suffered adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00191815",
        "8e91e404-086e-4063-8d54-83d1b8ebd969",
        "29b2fa29-5a76-4877-95bb-1a8de7973d33",
        "over 1/6 patients in cohort 1 of the primary trial suffered adverse events",
        "Only 6/67 patients in cohort 1 of the primary trial suffered adverse events",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00191815",
        "8e91e404-086e-4063-8d54-83d1b8ebd969",
        "8e91e404-086e-4063-8d54-83d1b8ebd969_b",
        "over 1/6 patients in cohort 1 of the primary trial suffered adverse events",
        "Adverse events occurred in more than 1/6 patients in cohort 1 of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00900627",
        "1f6a14ae-e22b-4b40-b389-217570dbf38e",
        "1f6a14ae-e22b-4b40-b389-217570dbf38e_b",
        "50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities ",
        "Dose- limiting toxicities occurred in 50% of cohort 2 patients in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00900627",
        "1f6a14ae-e22b-4b40-b389-217570dbf38e",
        "09fc4356-6154-427e-b710-ed5df6470aff",
        "50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities ",
        "50% of cohort 2 patients in the primary trial suffered Keratitis",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00900627",
        "09fc4356-6154-427e-b710-ed5df6470aff",
        "1f6a14ae-e22b-4b40-b389-217570dbf38e",
        "50% of cohort 2 patients in the primary trial suffered Keratitis",
        "50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities ",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00900627",
        "09fc4356-6154-427e-b710-ed5df6470aff",
        "09fc4356-6154-427e-b710-ed5df6470aff_b",
        "50% of cohort 2 patients in the primary trial suffered Keratitis",
        "Keratitis was present in 50% of cohort 2 patients in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00263588",
        "5c1e360c-fd93-4dd4-b855-71ba416d34cb",
        "5c1e360c-fd93-4dd4-b855-71ba416d34cb_b",
        "patients must be able to receive medication orally to participate in the primary trial",
        "Patients must be able to take the drug orally to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00263588",
        "5c1e360c-fd93-4dd4-b855-71ba416d34cb",
        "215a5c4a-d90c-4500-8284-0679ce311734",
        "patients must be able to receive medication orally to participate in the primary trial",
        "patients must have HER2- breast cancer to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00263588",
        "215a5c4a-d90c-4500-8284-0679ce311734",
        "5c1e360c-fd93-4dd4-b855-71ba416d34cb",
        "patients must have HER2- breast cancer to participate in the primary trial",
        "patients must be able to receive medication orally to participate in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00263588",
        "215a5c4a-d90c-4500-8284-0679ce311734",
        "215a5c4a-d90c-4500-8284-0679ce311734_b",
        "patients must have HER2- breast cancer to participate in the primary trial",
        "Patients must have HER2- breast cancer to participate in primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00944047",
        "48f516ff-abb4-4312-9b00-02f53fb16218",
        "48f516ff-abb4-4312-9b00-02f53fb16218_b",
        "under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        "A quarter of the primary trial patients in the intervention arm experienced a pathologic complete response",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00944047",
        "48f516ff-abb4-4312-9b00-02f53fb16218",
        "9f7d476e-9db3-4c00-abe6-4c2f0160470a",
        "under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        "under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00944047",
        "9f7d476e-9db3-4c00-abe6-4c2f0160470a",
        "48f516ff-abb4-4312-9b00-02f53fb16218",
        "under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        "under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00944047",
        "9f7d476e-9db3-4c00-abe6-4c2f0160470a",
        "9f7d476e-9db3-4c00-abe6-4c2f0160470a_b",
        "under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        "Fewer than 30% of patients in the primary trial in the intervention arm experienced a pathologic complete response",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01581619_NCT00106002",
        "0a6d1b4c-244e-44e2-a229-62e4cbdfa979",
        "0a6d1b4c-244e-44e2-a229-62e4cbdfa979_b",
        "the results of the secondary trial and the primary trial are non-comparable",
        "The results of the second trial are not comparable to the results of the first trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01581619_NCT00106002",
        "0a6d1b4c-244e-44e2-a229-62e4cbdfa979",
        "1180dd58-61b8-4c48-ab00-7d458e68c85b",
        "the results of the secondary trial and the primary trial are non-comparable",
        "the results of the secondary trial and the primary trial report the same outcome measures",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01581619_NCT00106002",
        "1180dd58-61b8-4c48-ab00-7d458e68c85b",
        "0a6d1b4c-244e-44e2-a229-62e4cbdfa979",
        "the results of the secondary trial and the primary trial report the same outcome measures",
        "the results of the secondary trial and the primary trial are non-comparable",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01581619_NCT00106002",
        "1180dd58-61b8-4c48-ab00-7d458e68c85b",
        "1180dd58-61b8-4c48-ab00-7d458e68c85b_b",
        "the results of the secondary trial and the primary trial report the same outcome measures",
        "The results of the secondary trial and the primary trial report the same outcome measure",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00333775",
        "9bcc31df-c1f6-4785-9235-f673213acf3a",
        "9bcc31df-c1f6-4785-9235-f673213acf3a_b",
        "both the primary trial cohorts receive identical doses of Docetaxel ",
        "Both primary trial cohorts received the same dose of docetaxel",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00333775",
        "9bcc31df-c1f6-4785-9235-f673213acf3a",
        "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d",
        "both the primary trial cohorts receive identical doses of Docetaxel ",
        "both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00333775",
        "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d",
        "9bcc31df-c1f6-4785-9235-f673213acf3a",
        "both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo",
        "both the primary trial cohorts receive identical doses of Docetaxel ",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00333775",
        "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d",
        "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d_b",
        "both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo",
        "Both primary trial cohorts received the same dose of docetaxel and cohort 1 also received 100 mg/m^2 placebo",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00904033",
        "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9",
        "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9_b",
        "neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention",
        "Neither cohort in the primary trial required surgery or received any oral medications as part of the intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00904033",
        "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9",
        "0a079cca-abde-42cf-9cec-a76e7a380e14",
        "neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention",
        "neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00904033",
        "0a079cca-abde-42cf-9cec-a76e7a380e14",
        "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9",
        "neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention",
        "neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00904033",
        "0a079cca-abde-42cf-9cec-a76e7a380e14",
        "0a079cca-abde-42cf-9cec-a76e7a380e14_b",
        "neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention",
        "Neither cohort in the primary trial required surgery as part of the intervention",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00232505",
        "75cf4ec2-9f2b-4d5b-8772-af247eaca07b",
        "75cf4ec2-9f2b-4d5b-8772-af247eaca07b_b",
        "Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial",
        "Patients with histologically confirmed stage I-III breast cancer were not eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00232505",
        "75cf4ec2-9f2b-4d5b-8772-af247eaca07b",
        "3cb71095-8e01-40dc-bbf5-eeffed55f354",
        "Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial",
        "Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00232505",
        "3cb71095-8e01-40dc-bbf5-eeffed55f354",
        "75cf4ec2-9f2b-4d5b-8772-af247eaca07b",
        "Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial",
        "Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00232505",
        "3cb71095-8e01-40dc-bbf5-eeffed55f354",
        "3cb71095-8e01-40dc-bbf5-eeffed55f354_b",
        "Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial",
        "Patients with histologically confirmed stage I-IV breast cancer were not eligible for the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01224678_NCT01042535",
        "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32",
        "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32_b",
        "There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial",
        "of mental health disorder, pleuropericarditis, atrial thrombosis and anemia in the secondary trial compared with the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01224678_NCT01042535",
        "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32",
        "b8322b23-a4f6-4cba-9761-be826b509de7",
        "There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial",
        "There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01224678_NCT01042535",
        "b8322b23-a4f6-4cba-9761-be826b509de7",
        "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32",
        "There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial",
        "There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01224678_NCT01042535",
        "b8322b23-a4f6-4cba-9761-be826b509de7",
        "b8322b23-a4f6-4cba-9761-be826b509de7_b",
        "There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial",
        "There were more cases of eye disease, abdominal pain, febrile neutropenia and anemia in the secondary trial compared with the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00820222",
        "5de9caeb-9dd5-4535-8fe3-289450d9c626",
        "5de9caeb-9dd5-4535-8fe3-289450d9c626_b",
        "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.",
        "primary trial results showed that the proportion of patients with CNS metastases was higher in the trastuzumab plus capecitabine group than in the lapatinib plus capecitabine group.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00820222",
        "5de9caeb-9dd5-4535-8fe3-289450d9c626",
        "566bdc2d-7c4a-4547-87da-ac81447ecca8",
        "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.",
        "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00820222",
        "566bdc2d-7c4a-4547-87da-ac81447ecca8",
        "5de9caeb-9dd5-4535-8fe3-289450d9c626",
        "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.",
        "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00820222",
        "566bdc2d-7c4a-4547-87da-ac81447ecca8",
        "566bdc2d-7c4a-4547-87da-ac81447ecca8_b",
        "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.",
        "a higher proportion of patients in the trastuzumab plus capecitabine group experienced grade 3 or 4 cutaneous/subcutaneous or pulmonary toxicity compared with the lapatinib plus capecitabine group.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00091442_NCT01439945",
        "bebfc78e-b35f-4677-8342-9567a7e795a1",
        "bebfc78e-b35f-4677-8342-9567a7e795a1_b",
        "There is one case of Diarrhea in the secondary trial and none in the primary trial",
        "1 case of diarrhea in the secondary trial and none in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00091442_NCT01439945",
        "bebfc78e-b35f-4677-8342-9567a7e795a1",
        "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3",
        "There is one case of Diarrhea in the secondary trial and none in the primary trial",
        "There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00091442_NCT01439945",
        "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3",
        "bebfc78e-b35f-4677-8342-9567a7e795a1",
        "There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts",
        "There is one case of Diarrhea in the secondary trial and none in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00091442_NCT01439945",
        "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3",
        "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3_b",
        "There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts",
        "only one case of diarrhea in the secondary trial, more than 14 different types of Aes were documented in the cohort of the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02301988",
        "faa65e54-aa04-4595-8dae-05cf00b4c887",
        "faa65e54-aa04-4595-8dae-05cf00b4c887_b",
        "Only cohort 1 patients of the primary trial are administered Ipatasertib",
        "Only patients in Cohort 1 of the primary trial received Ipatasertib",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02301988",
        "faa65e54-aa04-4595-8dae-05cf00b4c887",
        "973f090a-8967-4d75-bb8e-6166c868337c",
        "Only cohort 1 patients of the primary trial are administered Ipatasertib",
        "cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02301988",
        "973f090a-8967-4d75-bb8e-6166c868337c",
        "faa65e54-aa04-4595-8dae-05cf00b4c887",
        "cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients",
        "Only cohort 1 patients of the primary trial are administered Ipatasertib",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02301988",
        "973f090a-8967-4d75-bb8e-6166c868337c",
        "973f090a-8967-4d75-bb8e-6166c868337c_b",
        "cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients",
        "Patients in cohort 1 of the primary trial received higher doses of ipatasertib compared with placebo in cohort 2 patients",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01928186_NCT02340221",
        "49ba06b2-576d-4db2-80b6-51673416f2ba",
        "49ba06b2-576d-4db2-80b6-51673416f2ba_b",
        "the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts",
        "Primary and secondary trials measure percent change in net inflow constant (Ki) by FLT PET in their patient cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT01928186_NCT02340221",
        "49ba06b2-576d-4db2-80b6-51673416f2ba",
        "2a03c17f-3afe-40f1-a0db-4b876ee8c700",
        "the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts",
        "the primary trial and the secondary trial have non-comparable outcome measurements for their results",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01928186_NCT02340221",
        "2a03c17f-3afe-40f1-a0db-4b876ee8c700",
        "49ba06b2-576d-4db2-80b6-51673416f2ba",
        "the primary trial and the secondary trial have non-comparable outcome measurements for their results",
        "the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT01928186_NCT02340221",
        "2a03c17f-3afe-40f1-a0db-4b876ee8c700",
        "2a03c17f-3afe-40f1-a0db-4b876ee8c700_b",
        "the primary trial and the secondary trial have non-comparable outcome measurements for their results",
        "Outcome measures of the primary and secondary trials are not comparable",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00688909_NCT00450723",
        "f0e845f9-8991-45b5-a520-51e934756f7a",
        "f0e845f9-8991-45b5-a520-51e934756f7a_b",
        "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "The primary trial intervention involved an oral drug , and the secondary trial intervention was based on a medical procedure.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00688909_NCT00450723",
        "f0e845f9-8991-45b5-a520-51e934756f7a",
        "d310ec4e-993e-4827-8dc5-9aca053972db",
        "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00688909_NCT00450723",
        "d310ec4e-993e-4827-8dc5-9aca053972db",
        "f0e845f9-8991-45b5-a520-51e934756f7a",
        "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00688909_NCT00450723",
        "d310ec4e-993e-4827-8dc5-9aca053972db",
        "d310ec4e-993e-4827-8dc5-9aca053972db_b",
        "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "The primary trial intervention involved an oral drug , and the secondary trial intervention was based on a medical procedure.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00106002",
        "1d1f57f8-85f7-448c-a4bb-15957da568fd",
        "1d1f57f8-85f7-448c-a4bb-15957da568fd_b",
        "the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression",
        "The primary trial intervention will continue until patients achieve complete remission or disease progression",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00106002",
        "1d1f57f8-85f7-448c-a4bb-15957da568fd",
        "236780db-9e59-4dc9-8da0-e786287011cf",
        "the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression",
        "the primary trial intervention protocol lasts a total of 14 days",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00106002",
        "236780db-9e59-4dc9-8da0-e786287011cf",
        "1d1f57f8-85f7-448c-a4bb-15957da568fd",
        "the primary trial intervention protocol lasts a total of 14 days",
        "the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00106002",
        "236780db-9e59-4dc9-8da0-e786287011cf",
        "236780db-9e59-4dc9-8da0-e786287011cf_b",
        "the primary trial intervention protocol lasts a total of 14 days",
        "The primary trial intervention protocol lasted a total of 14 days",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02370238",
        "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7",
        "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7_b",
        "There were more total AEs in cohort 1 of  the primary trial than cohort 2",
        "Total AEs in more than cohort 2",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT02370238",
        "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7",
        "2da13cd4-7189-4f85-be4d-5c1e213ae293",
        "There were more total AEs in cohort 1 of  the primary trial than cohort 2",
        "The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02370238",
        "2da13cd4-7189-4f85-be4d-5c1e213ae293",
        "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7",
        "The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.",
        "There were more total AEs in cohort 1 of  the primary trial than cohort 2",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT02370238",
        "2da13cd4-7189-4f85-be4d-5c1e213ae293",
        "2da13cd4-7189-4f85-be4d-5c1e213ae293_b",
        "The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.",
        "The most common AE in the primary trial was noncardiac chest pain, which affected less than 5% of participants in cohort 1.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00217399",
        "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7",
        "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7_b",
        "All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        "All patients in the primary trial achieved disappearance of all target lesions, a reduction in the sum of the longest diameters of target lesions >= 30%, or tumors that neither grew nor shrunk.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ],
    [
        "NCT00217399",
        "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7",
        "985bc5a0-bc21-447f-92f1-150e23ede3f5",
        "All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        "All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00217399",
        "985bc5a0-bc21-447f-92f1-150e23ede3f5",
        "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7",
        "All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions",
        "All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        0
    ],
    [
        "NCT00217399",
        "985bc5a0-bc21-447f-92f1-150e23ede3f5",
        "985bc5a0-bc21-447f-92f1-150e23ede3f5_b",
        "All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions",
        "At least a 50% reduction in the sum of the longest diameters of target lesions in all patients in the primary trial",
        [
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ],
            [
                "Adverse Events 1:",
                "  Total: 10/48 (20.83%)",
                "  NEUTROPENIA 1/48 (2.08%)",
                "  THROMBOCYTOPENIA 0/48 (0.00%)",
                "  VOLUME BLOOD DECREASED 1/48 (2.08%)",
                "  FIBRILLATION ATRIAL 1/48 (2.08%)",
                "  HYPOTENSION 1/48 (2.08%)",
                "  ABDOMINAL PAIN 1/48 (2.08%)",
                "  APPETITE DECREASED 0/48 (0.00%)",
                "  DEHYDRATION 4/48 (8.33%)",
                "  DIARRHEA 4/48 (8.33%)",
                "  NAUSEA 3/48 (6.25%)",
                "  VOMITING 2/48 (4.17%)",
                "  FEVER 1/48 (2.08%)",
                "  RIGORS 0/48 (0.00%)",
                "Adverse Events 2:",
                "  Total: 5/53 (9.43%)",
                "  NEUTROPENIA 1/53 (1.89%)",
                "  THROMBOCYTOPENIA 1/53 (1.89%)",
                "  VOLUME BLOOD DECREASED 0/53 (0.00%)",
                "  FIBRILLATION ATRIAL 0/53 (0.00%)",
                "  HYPOTENSION 0/53 (0.00%)",
                "  ABDOMINAL PAIN 0/53 (0.00%)",
                "  APPETITE DECREASED 1/53 (1.89%)",
                "  DEHYDRATION 0/53 (0.00%)",
                "  DIARRHEA 0/53 (0.00%)",
                "  NAUSEA 1/53 (1.89%)",
                "  VOMITING 1/53 (1.89%)",
                "  FEVER 1/53 (1.89%)",
                "  RIGORS 1/53 (1.89%)"
            ]
        ],
        1
    ]
]